Originally published In Press as doi:10.1074/jbc.M202434200 on April 11, 2002
J. Biol. Chem., Vol. 277, Issue 25, 22934-22941, June 21, 2002
A Novel PDZ Protein Regulates the Activity of Guanylyl Cyclase C,
the Heat-stable Enterotoxin Receptor*
Robert O.
Scott
,
William R.
Thelin, and
Sharon L.
Milgram§
From the Department of Cell and Developmental Biology, University
of North Carolina, Chapel Hill, North Carolina 27599
Received for publication, March 13, 2002, and in revised form, April 9, 2002
 |
ABSTRACT |
Secretory diarrhea is the leading cause of
infectious diarrhea in humans. Secretory diarrhea may be caused by
binding of heat-stable enterotoxins to the intestinal receptor
guanylyl cyclase C (GCC). Activation of GCC catalyzes the formation of
cGMP, initiating a signaling cascade that opens the cystic fibrosis
transmembrane conductance regulator chloride channel at the apical cell
surface. To identify proteins that regulate the trafficking or function of GCC, we used the unique COOH terminus of GCC as the "bait" to
screen a human intestinal yeast two-hybrid library. We identified a
novel protein, IKEPP (intestinal and
kidney-enriched PDZ
protein) that associates with the COOH terminus of GCC in
biochemical assays and by co-immunoprecipitation. IKEPP is expressed in
the intestinal epithelium, where it is preferentially accumulated at
the apical surface. The GCC-IKEPP interaction is not required for the
efficient targeting of GCC to the apical cell surface. Rather, the
association with IKEPP significantly inhibits heat-stable
enterotoxin-mediated activation of GCC. Our findings are the first to
identify a regulatory protein that associates with GCC to modulate the
catalytic activity of the enzyme and provides new insights in
mechanisms that regulate GCC activity in response to bacterial toxin.
 |
INTRODUCTION |
Guanylyl cyclase C (GCC) is the receptor for heat-stable
enterotoxins (STa)1 secreted
by Escherichia coli and other enteric bacteria. STa binding
to GCC increases intracellular cGMP and initiates a signaling cascade,
leading to the phosphorylation of the cystic fibrosis transmembrane
conductance regulator (CFTR) at the apical surface of gastrointestinal
epithelial cells. Phosphorylation of CFTR opens the channel, resulting
in the net efflux of ions and water into the intestinal lumen. The
endogenous ligands for GCC include guanylin, uroguanylin, and
lymphoguanylin, which are thought to regulate ion transport in
epithelial tissues (1-3).
GCC is a member of a family of transmembrane proteins that includes
receptors for natriuretic peptides and egg-activating peptides as well
as several orphan receptors (4). All receptor GCs with a single
transmembrane domain share a common topology. There is an
NH2-terminal extracellular ligand-binding domain and a
large cytosolic domain composed of a kinase homology domain and a
catalytic domain. Following the catalytic domain, GCC contains an
extended COOH terminus of 63 amino acids
(COOH-terminal extension peptide (CTEP)) that is not found in the natriuretic
peptide receptors (5). The CTEP is well conserved and contains a
consensus protein kinase C phosphorylation site that potentiates
cGMP-mediated signaling by phorbol esters (6). GCC proteins lacking the
63-amino acid CTEP lose the ability to respond to STa (6, 7),
suggesting that this unique sequence plays a role in GCC activation.
Since GCC is the only receptor guanylyl cyclase localized predominately at the apical membrane of epithelial cells, CTEP may also play a role
targeting the receptor to the apical cell surface.
To determine whether the COOH terminus of GCC participates in
protein-protein interactions that may regulate its targeting or
function, we screened a human intestinal epithelial enriched yeast
two-hybrid library using CTEP as "bait." We found that GCC associates via its COOH terminus with a novel protein containing four
PDZ domains. Based on its domain organization and restricted mRNA
distribution, we named this protein IKEPP (intestinal and kidney enriched PDZ
Protein). IKEPP is accumulated at the apical membrane of
human intestinal epithelial cells and associates with GCC in a cellular
context. Mutagenesis studies indicate that association with PDZ
proteins is not required for efficient targeting of GCC to the apical
surface. Rather, the interaction of IKEPP and GCC inhibits receptor
activation by STa. Thus, GCC activity may be modulated by interaction
with accessory proteins, thereby providing additional means to regulate
signaling via guanylyl cyclase receptors.
 |
EXPERIMENTAL PROCEDURES |
cDNA Library Generation, Plasmid Construction, Two-hybrid
Screens--
All cDNA inserts were generated by PCR, cloned into
complementary restriction endonuclease sites of the appropriate
plasmids, and verified by sequencing; specific details are available
upon request. A human intestinal epithelial enriched cDNA library
was generated by cloning poly(dT)-primed cDNA into the HybriZAP
bacteriophage
vector followed by amplification and in
vivo mass excision to generate a two-hybrid library in pAD-GAL4
(Stratagene). The yeast binding domain (BD) plasmid pPC86BD was
generated by digesting the parental vectors, pPC97 (GAL4BD and LEU2)
and pPC86 (GAL4AD and TRP1) (8), with ApaI and
BamHI. These fragments were then ligated into the opposite
backbone vector to give pPC86BD and pPC97AD.
cDNA encoding full-length CTEP was amplified by PCR using
pBS.GCC as template; the PCR products were inserted in frame to the
corresponding sites in pPC86BD. The yeast strain AH109 was sequentially
transformed with pPC86BD.CTEP and 20 µg of a human intestinal
cDNA library as described (9). A ~2.2-kb cDNA clone encoding
a novel protein was isolated twice in the screen. After sequencing and
Northern blot analysis, this clone was named IKEPP (intestinal and kidney enriched
PDZ protein). To obtain upstream coding
sequences we performed 5' rapid amplification of cDNA ends using
Marathon-Ready Human Kidney cDNA (CLONTECH);
products were cloned into pTAdv (CLONTECH) and
sequenced. Human multiple tissue northern blots and a multiple
expression array blot (CLONTECH) were probed with
32P-labeled random-primed cDNA probe corresponding to
the IKEPP 3'-untranslated region (nucleotides 1565-2120) as
described (10).
Antisera Generation and Immunoblot Analysis--
Rabbit antisera
directed against the COOH terminus of human IKEPP were generated in
rabbits using residues 484-505 of IKEPP coupled with keyhole limpet
cyanin as immunogen. Rabbit polyclonal antisera were also generated
using His-IKEPP fusion protein as immunogen. The pET.IKEPP plasmid was
transformed into BL21(DE3, pLysS) Escherichia coli and grown
to the appropriate cell density at 37 °C. IKEPP expression was
induced by the addition of 1 mM isopropyl-1-thio-
-D-galactopyranoside for 3 h at
37 °C and purified from the insoluble fraction.
To prepare cell lysates, cultured cells were washed with ice-cold
phosphate-buffered saline (50 mM NaPO4, 150 mM NaCl, pH 7.4) and isolated by scraping in ice-cold
homogenization buffer containing 20 mM Hepes, pH 7.4, 150 mM NaCl, 2 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin. The homogenates were centrifuged at 100,000 × g for 1 h to generate soluble and particulate
fractions. Protein concentrations were determined using the BCA protein
assay kit (Pierce); samples were fractionated by SDS-PAGE and
transferred to Immobilon-P (Millipore Corp.). Western blots were
performed using rabbit anti-IKEPP IgG (NC368 or NC369; 1:2000) and
visualized using ECL.
Protein Interaction Assays--
In vitro binding
assays and co-immunoprecipitations were performed as described (11).
For immunoprecipitation of overexpressed HA-GCC and IKEPP, COS7 cells
were transfected with cDNAs encoding IKEPP and HA-GCC or HA-GCC
4
with FuGENE6 (Roche Molecular Biochemicals). After 48 h, the cells
were lysed in TBS (100 mM Tris-HCl, 150 mM
NaCl, pH 7.5), 1% Triton X-100, and protease inhibitors. Mouse anti-HA
or purified normal mouse IgG (2 µg) was added to the cell lysate and
incubated overnight at 4 °C. Immune complexes were collected on
protein G-agarose and washed extensively in TBS buffer plus 0.1%
Triton X-100. Bound proteins were resolved by SDS-PAGE and analyzed by
Western blotting with HA or IKEPP antisera.
Confocal Microscopy--
Stable MCDK type II cell lines
expressing HA-GCC or HA-GCC
4 were generated as described (10). MDCK
or Caco2 cells were grown on Transwell filters (Costar) until confluent
monolayers were observed, and transepithelial resistances, with filter
subtraction, were greater than 1000 ohms·cm2 or 400 ohms·cm2, respectively. Immunofluorescent staining was
performed as described (10, 11). The localization of IKEPP was also
studied in sections of formalin-fixed human colon and small intestine.
Sections were prepared as described previously (12), stained with
rabbit anti-IKEPP IgG (NC369; diluted 1:1500), and processed using the
Vectastain Elite ABC kit (Vector Laboratories, Inc.); sections were
counterstained with methyl green to label nuclei.
GCC Activity Assays--
COS7 cells, plated on six-well culture
dishes at a density of 4 × 105 24 h prior to
transfection, were incubated in FuGENE 6 as described in the
instruction manual. After 48 h, the culture medium was removed,
the cells were incubated in serum-free Dulbecco's modified Eagle's
medium/F-12 containing 100 µM isobutylmethylxanthine for 15 min, and 25 units/ml STa (Sigma) was added to each well for 20 min.
The cells were washed twice in ice-cold phosphate-buffered saline,
lysed in 0.1 M HCl for 20 min, and collected by
centrifugation at 4 °C. For dose-response curves, cells were handled
as described except that 2 × 105 cells were seeded in
12-well culture dishes 24 h prior to transfection. Following
transfection, STa was added to the cells at various concentrations for
30 min in the presence of 100 µM isobutylmethylxanthine. Cells were harvested, and cGMP production was measured in both the cell
lysate and culture medium using a Correlate-EIA Direct Cyclic GMP
Enzyme Immunoassay Kit (Assay Designs, Inc.).
 |
RESULTS |
Cloning and Characterization of a Novel GCC-interacting
Protein--
In an attempt to isolate GCC-interacting proteins, we
used the yeast two-hybrid system to identify proteins that interact with the CTEP of GCC. Screening of a human epithelial enriched intestinal cDNA library yielded several potential interactors that
were His+, and we further analyzed two clones that
exhibited robust
-galactosidase activity. The specificity of the
interaction in yeast was verified by transforming the activation domain
plasmid along with the original bait, an empty bait vector, or a
plasmid encoding an unrelated bait (data not shown).
Sequence analysis revealed that the cDNA inserts were ~2.4 kb and
contained identical cDNA sequence with an open reading frame of
1503 nucleotides. A protein pattern search using Pfam indicated that
the open reading frame encoded a protein containing four PDZ domains.
The gene was mapped to a region of chromosome 11q23 when searched
against the human genome draft data base. The full-length cDNA with
an open reading frame of 1518 nucleotides was predicted from genomic
DNA and confirmed by 5' rapid amplification of cDNA ends using
human kidney cDNA as template. The open reading frame predicts a
protein of 505 amino acids with a theoretical molecular mass of 54.2 kilodaltons and a pI of 5.46.
On Northern blots, we detected ~2.3- and 2.5-kb messages in human
kidney (Fig. 1A), although
prolonged exposures of the blots revealed that the mRNAs were also
expressed in the small intestine and colon. Since GCC mRNA is
abundantly expressed in the intestine (5), we also probed a human
expression array containing poly(A)+ RNA prepared from
multiple gastrointestinal tissues. We found that mRNA was easily
detected in the kidney and along the entire gastrointestinal tract,
from the duodenum to the colon (Fig. 1B). The mRNA was
not detected in any other human tissue including brain, heart, skeletal
muscle, or cells of hematopoietic origin (data not shown). Based on the
relatively restricted distribution of the mRNA and the domain
structure of the predicted protein, we named this novel protein IKEPP.

View larger version (73K):
[in this window]
[in a new window]
|
Fig. 1.
Identification of a novel PDZ protein
preferentially expressed in the intestine and kidney. A, a
multiple tissue Northern blot (CLONTECH) was probed
with a random primed 32P-labeled probe generated against
the IKEPP 3'-untranslated region. The blot was stripped and incubated
with a -actin probe. Similar results were obtained in two separate
blots. B, a multiple tissue array was probed with the same IKEPP probed
used in A; all other tissues showed no signal and were
deleted from the figure. C, schematic
representation of IKEPP and related PDZ proteins. PDZ domains are
numbered, and ezrin-radixin-moesin binding motifs are indicated by the
letter E. The proteins are drawn to scale, and the amino
acid numbers are as shown. D, the amino acid sequences of
the individual PDZ domains of IKEPP, PDZK1, EBP50, and E3KARP were
aligned using DNASTAR software. At each position, the most commonly
conserved residues between sequences are shown in black
boxes, whereas similarly charged residues are
shaded in gray. The predicted secondary
structures of the PDZ domains, based on the crystal structure of EBP50
PDZ1 are also shown.
|
|
IKEPP Is Related to Other Epithelial Enriched PDZ Proteins--
A
BLAST search of the nonredundant GenBankTM data base with
the IKEPP protein sequence revealed that IKEPP is most closely related to PDZK1 (PDZ domain containing protein-1; also called CAP70), a
protein with four PDZ domains (13, 14). IKEPP and PDZK1 are closely
related to two other human epithelial PDZ proteins, EBP50
(ezrin-radixin-moesin-binding
phosphoprotein-50; also called NHERF1) and
E3KARP (NHE3 kinase A
regulatory protein; also called NHERF2), which
each contain two PDZ domains (Fig. 1C) followed by a
COOH-terminal domain that associates with the NH2 terminus of ezrin, radixin, and moesin to link these proteins to the actin cytoskeleton (15). An analysis of the sequence identity between the
individual IKEPP PDZ domains and the PDZ domains of EBP50, E3KARP, and
PDZK1 indicates that PDZ1 and PDZ4 of IKEPP are most unique, whereas
PDZ2 and PDZ3 of IKEPP share between 30 and 50% identity with the PDZ
domains of these related proteins (Fig. 1D). Furthermore,
IKEPP is probably the human orthologue of the mouse type IIa
sodium/inorganic phosphate cotransporter-associated protein
(Na/Pi-Cap2), since both proteins contain four tandem PDZ domains,
share 77% sequence identity, and are expressed in the kidney and
intestine (16).
PDZ domains are composed of six
sheets (
A-
F), capped by two
helices (
A and
B), which form a peptide-binding groove that interacts with, at least, the last four C-terminal amino acids of
interacting proteins (17). In general, PDZ domains recognize peptide
sequences that contain a hydrophobic residue at the extreme COOH
terminus through a conserved carboxylate-binding pocket most often
formed by the sequence
Arg/Lys-X-X-X-
-Gly-Phe (where
represents a hydrophobic amino acid) (18). The carboxylate loop of PDZ
domains in IKEPP, PDZK1, EBP50, and E3KARP contain the general
consensus, Arg/Lys-X-X-Tyr/Phe-Gly-Phe, with the
exception of IKEPP PDZ4, which possesses a Pro residue rather than the
Arg/Lys (Fig. 1D). In the carboxylate-binding pocket, the
Arg/Lys residue is responsible for ordering a water molecule that
interacts with the terminal carboxylate of the ligand (17). Therefore,
the C-terminal residue(s) of proteins that associate with IKEPP PDZ4 will probably differ from the ligands recognized by PDZK1, EBP50, E3KARP, and IKEPP PDZ domains 1-3.
The
2-position of the preferred peptide ligand is used to categorize
the PDZ domains as class I (
2 Ser/Thr), class II (
2 hydrophobic),
and a lesser defined class III, which deviate from class I and II
(18-20). The specificity of the
2 interaction is coordinated by the
first residue of the second
helix of the PDZ domain (
B1) (18).
At the
B1 position, class I PDZ domains contain a conserved His
residue (17, 21), whereas class II domains possess a hydrophobic
residue (22). To the best of our knowledge, all of the published
binding partners of PDZK1, EBP50, and E3KARP, as well as the binding
partners our laboratory has identified for IKEPP, contain a Ser/Thr at
the
2-position of the PDZ binding motif. Based on this structural
similarity, we predict that IKEPP is a member of the superfamily of
class I PDZ proteins. Sequence analysis of the individual PDZ domains
of IKEPP, however, reveals that IKEPP PDZ1 and PDZ4 lack the conserved
His residue characteristic of class I PDZ domains. In the
B1
position, a Tyr residue (IKEPP PDZ1) has been shown to prefer ligands
containing a
2 Asp residue, whereas an Asp residue (IKEPP PDZ4)
interacts with peptides with a
2 Tyr (20, 23).
Localization and Distribution of IKEPP in Human Cells and
Tissues--
To evaluate the subcellular distribution of IKEPP, we
generated rabbit polyclonal antisera directed against the COOH-terminal 15 amino acids of human IKEPP or the recombinant full-length protein. These antisera were first tested by Western blot analysis using full-length human IKEPP generated by coupled in vitro
transcription/translation. Whereas preimmune sera did not detect
proteins in the reticulocyte lysates, both antibodies reliably detected
full-length IKEPP (Fig. 2A).
We further tested the specificity of our IKEPP antisera by Western blot
analysis of EBP50, E3KARP, and PDZK1 and found that both IKEPP antisera
specifically recognize recombinant IKEPP and do not cross-react with
these related proteins (Fig. 2A). Recombinant E3KARP
contains fewer methionine residues than IKEPP, PDZK1, and EBP50 and was
visualized with prolonged exposure to the PhosphorImager screen.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 2.
Characterization of IKEPP antisera and
analysis of IKEPP protein expression. A, radiolabeled
IKEPP, PDZK1, EBP50, and E3KARP were generated by in
vitro transcription/translation in the presence of
[35S]methionine. Five µl of each reaction was analyzed
by Western blot with antisera generated using full-length recombinant
IKEPP (NC368) or IKEPP residues 484-505 (NC369); the same membrane was
analyzed by PhosphorImager analysis (35S
Met). Recombinant E3KARP contains fewer methionine residues
but is visualized with prolonged exposure to the screen. B,
whole cell lysates (50 µg) were analyzed by Western blot with rabbit
anti-IKEPP (NC 368; 1:1000) or mouse anti-actin. C, cultured
T84 and Caco-2 cells were lysed in homogenization buffer plus protease
inhibitors, and soluble and particulate fractions were prepared by
differential centrifugation. Equal ratios of each fraction were
analyzed by Western blot using NC368 (1:1000). Each blot is
representative of three or four experiments.
|
|
We first examined the expression of IKEPP in cultured human cell lines
and found that the protein was expressed in whole cell lysates of two
intestinal epithelial cell lines, T84 and Caco2 (Fig. 2B);
much less protein was detected in an airway epithelial cell line
(16HBE14o
) or in hEK293 cells. A significant fraction of the IKEPP
protein was found in the particulate fraction of Caco2 and T84 cells
(Fig. 2C). We next examined the localization of IKEPP in
Caco2 cells grown to confluence on Transwell filters and found IKEPP
preferentially accumulated in the subapical compartment and at the
apical membrane (Fig.
3A); similar results were
obtained with colonic T84 cells (data not shown). In normal human ileum and colon, IKEPP was preferentially accumulated at the apical surface
and was visualized in cells of the crypt and villus (Fig. 3B). GCC is also expressed at the apical surface of
intestinal epithelial cells (24). Thus, the distribution of IKEPP in
human intestine is consistent with the possibility that the GCC and IKEPP associate in vivo.

View larger version (103K):
[in this window]
[in a new window]
|
Fig. 3.
Localization of IKEPP. A,
Caco-2 cells grown on Transwell filters were fixed, permeabilized,
blocked, and stained with preimmune antisera or rabbit
anti-IKEPP (NC369; 1:1500) followed by goat anti-rabbit IgG coupled
with Oregon Green (1:500). Texas Red-conjugated phalloidin (1:500) was
added to stain filamentous actin, and xz sections were
analyzed by confocal microscopy (scale bar, 10 µm). B, representative paraffin-embedded 6-µm sections
of human colon (upper panels) or small intestine
(lower panels) were stained with preimmune
antisera or NC369 (1:1500). The arrows indicate regions of
specific staining. Sections were processed using Vectastain Elite ABC
kit (scale bar, 50 µm).
|
|
Characterization of the IKEPP-GCC Interaction--
We further
characterized the interaction between GCC and IKEPP. Since GCC
terminates with the amino acid sequence STYF, a type I PDZ binding
motif, we tested whether the COOH-terminal four amino acids of CTEP
mediated the interaction with IKEPP. We immobilized GST, GST-CTEP
full-length, or GST-CTEP
4 fusion proteins on glutathione-agarose
beads and incubated the affinity resins with radiolabeled IKEPP. We
found that IKEPP bound GST-CTEP but not GST or GST-CTEP
4 (Fig.
4A). We obtained similar
results in overlay assays (data not shown), indicating that the last
four amino acid residues (SYTF) of GCC are required for the direct association with IKEPP.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 4.
Analysis of the GCC-IKEPP interaction.
A, GST, GST-CTEP full-length (FL), or
GST-CTEP 4 ( 4) were immobilized on glutathione-agarose
beads and incubated with 5 µl of radiolabeled IKEPP. The bound
fractions were resolved by SDS-PAGE and applied to PhosphorImager
screen; the arrow indicates radiolabeled IKEPP.
B, radiolabeled IKEPP PDZ domains were incubated with
GST-CTEP full-length or GST-CTEP 4. The bound fraction was separated
by SDS-PAGE and visualized by PhosphorImager analysis. C,
GST-CTEP full-length and GST-CTEP 4 were immobilized on
glutathione-agarose beads and incubated with radiolabeled IKEPP, PDZK1,
EBP50, or E3KARP. Bound proteins were visualized by PhosphorImager
analysis. The bottom panels show 20% of the
input used in each reaction. E3KARP can be visualized with prolonged
exposure only in the input lane. D, ~200 µg of total
cell lysate prepared from cells expressing HA-GCC was incubated at
4 °C overnight with GST or GST-IKEPP. The bound fraction was
analyzed by Western blot using HA antibody. I, input,
representing 10% of the total cell lysate in each reaction.
E, COS7 cells were transfected with FUGENE6 plus 9 µg of
pCDNA.HA-GCC full-length or HA-GCC 4 and 13.5 µg of
pCDNA.IKEPP. Cell lysates were incubated with anti-mouse IgG or
monoclonal HA.11. Immunoprecipitates were analyzed by Western blot with
HA or IKEPP antisera. The IgG band is indicated by the
arrow, and molecular weight markers are as shown.
IP, the antibody used for immunoprecipitation. All
panels are representative of 3-6 similar experiments.
|
|
IKEPP has four PDZ domains that probably bind different ligands.
Therefore, we determined which IKEPP PDZ domains are capable of
associating with CTEP. To do this, we generated histidine-tagged fusion
proteins consisting of PDZ1, PDZ2, PDZ3, or PDZ4 of IKEPP and tested
which of the radiolabeled fusion proteins associated with full-length
GST-CTEP immobilized on glutathione-agarose beads. We found that
radiolabeled PDZ3 bound specifically to full-length GST-CTEP, but not
GST or GST-CTEP
4. This interaction was not detected for PDZ1, PDZ2,
and PDZ4 (Fig. 4B). Since IKEPP shares homology with EBP50,
E3KARP, and PDZK1, we immobilized GST-CTEP and GST-CTEP
4 on
glutathione-agarose beads and tested whether radiolabeled PDZK1, EBP50,
or E3KARP could associate with CTEP. We found that PDZK1,
but not EBP50 or E3KARP, associates with GST-CTEP in pull-down
assays (Fig. 4C).
To determine whether full-length IKEPP could associate with full-length
GCC, we incubated GST or GST-IKEPP with whole cell lysates prepared
from cells overexpressing HA-tagged GCC (HA-GCC). HA-GCC associated
with GST-IKEPP but not with GST (Fig. 4D). GCC may be
tightly associated with the subapical cytoskeleton in the intestinal
epithelium (25) and is not easily solubilized from cell membranes in
buffers compatible with maintaining protein-protein interactions.
Therefore we used an overexpression strategy to study the association
of GCC and IKEPP in nonepithelial cells. COS7 cells were transiently
transfected with cDNAs encoding IKEPP plus HA-GCC or IKEPP plus
HA-GCC
4. Cell lysates were prepared in buffers containing 1% Triton
X-100, which is known to remove GCC from cell membranes in COS7 cells
(5), and the cell lysates were incubated with control IgG or HA
antibody. We found that IKEPP was not associated with control IgG but
was easily detected in HA-GCC immunoprecipitates (Fig. 4E).
Moreover, IKEPP was not found in HA immunoprecipitates from cells
co-expressing HA-GCC
4 plus IKEPP (Fig. 4E). Thus, we
conclude that GCC and IKEPP associate in cells and that the association
requires an intact GCC COOH terminus.
Function of the GCC-IKEPP Interaction--
Interaction with PDZ
proteins may be involved in selectively targeting proteins to apical or
basolateral cell surfaces in epithelial cells (26-28). Therefore, we
tested whether the COOH-terminal STYF sequence in GCC was involved in
targeting the receptor to the apical cell surface. We generated stable
MDCK cell lines expressing HA-GCC or HA-GCC
4, lacking the STYF
residues that mediate interaction with PDZ proteins. Full-length HA-GCC
was targeted to the apical cell surface and was not detected at the
basolateral membrane (Fig.
5A). Likewise, HA-GCC
4 was
preferentially accumulated at the apical cell surface of polarized MDCK
cells (Fig. 5A). HA-GCC and HA-GCC
4 were visualized at
the apical membrane in nonpermeabilized cells, further suggesting that
the HA-GCC and HA-GCC
4 proteins were on the cell surface (data not
shown). Thus, we conclude that interaction with apical membrane PDZ
proteins does not play a significant role in the targeting of GCC to
the apical cell surface in MDCK cells.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
Targeting and activation of HA-GCC and
HA-GCC 4. A, localization of
HA-GCC in MDCK cells stably expressing HA-GCC (FL) or 4
HA-GCC ( 4); TRITC-conjugated phalloidin was added to
visualize actin. xy and xz sections were analyzed
by confocal microscopy (scale bar, 10 µm).
B, COS7 cells were transfected with 6 µg of
pCDNA.HA-GCC or pCDNA.HA-GCC 4 plus 9 µg of pCDNA.IKEPP
or empty vector. cGMP was assayed as described; n = 3 with duplicate measurements for each sample. Each bar
represents total cGMP, measured from cell lysates and culture medium.
Intracellular cGMP accounted for at least 93% of total cGMP measured
for each sample. A corresponding Western blot indicating the relative
expression of HA-GCC and IKEPP is also shown. C, COS7 cells
were transfected with pCDNA.HA-GCC plus pCDNA.IKEPP
(closed circles) or pCDNA.HA-GCC plus empty
vector (open circles). cGMP was measured from
triplicate experiments assayed in duplicate, and each data point
represents the mean ± S.E.
|
|
Bakre et al. recently compared the STa-induced
desenstitization of GCC in intestinal epithelial cells and in
transfected fibroblasts and suggested that GCC catalytic activity might
be regulated by interaction with proteins selectively expressed in
epithelial cells (29). Therefore, we tested whether IKEPP modulated
STa-mediated activation of GCC in transfected COS7 cells that do not
express significant amounts of endogenous IKEPP. Treatment of COS7
cells expressing HA-GCC with 25 units/ml STa for 20 min significantly increased intracellular cGMP, whereas cGMP was undetected in
mock-transfected cells (data not shown). In cells co-expressing GCC and
IKEPP, 25 units/ml STa also increased intracellular cGMP above
background. cGMP levels, however, were reduced by ~1.7-fold in cells
co-expressing HA-GCC and IKEPP compared with cells transfected with
HA-GCC and empty vector (Fig. 5B). In similar experiments,
intracellular cGMP levels were decreased in COS7 cells expressing GCC
and IKEPP by 1.5-2.5-fold compared with cells expressing HA-GCC and
empty vector following incubation with 25 units/ml STa for 10-30 min (data not shown). This cannot be explained by changes in the expression of HA-GCC in the co-transfected cells, since the receptor was easily
detected in membrane fractions prepared from these cells (Fig.
5B). Since the COOH terminus of GCC mediates the interaction with IKEPP, we tested whether IKEPP expression also inhibited STa-mediated activation of HA-GCC
4. We observed similar levels of
STa-mediated cGMP in HA-GCC
4 cells in the absence or presence of
co-expressed IKEPP (Fig. 5B). Therefore, we conclude that
IKEPP binding may inhibit the catalytic activity of GCC and that the inhibition requires a physical interaction between the receptor and
IKEPP. To begin to understand the mechanism of this inhibition, we
transfected COS7 cells with HA-GCC with or without IKEPP and assayed
cGMP accumulation over a range of STa concentrations. Application of
STa resulted in a concentration-dependent accumulation of
cGMP in cells expressing HA-GCC plus vector or HA-GCC plus IKEPP (Fig.
5C). Although we found no change in the
Vmax of the enzyme in the presence or absence of
co-expressed IKEPP, we found that IKEPP significantly increased the
amount of STa required for half-maximal activation of the enzyme (Fig.
5C). The half-maximal effect of STa on cGMP accumulation was
~30 nM in the absence of IKEPP and increased >10-fold
with co-expressed IKEPP, indicating that association with IKEPP
alters the function of the receptor.
 |
DISCUSSION |
We report the cloning and initial characterization of IKEPP, a
novel PDZ protein expressed at the apical membrane of human intestinal
epithelial cells. IKEPP directly associates with the COOH terminus of
GCC, the heat-stable enterotoxin receptor found at the apical surface
of intestinal epithelial cells. Our localization studies (Fig. 3) and
co-immunoprecipitation assays (Fig. 4E) support the
hypothesis that IKEPP and GCC may associate in cells. Furthermore, the
association with IKEPP inhibits the catalytic function of GCC,
resulting in a decreased responsiveness to STa (Fig. 5, B and C).
Sequence and structural analysis indicates that IKEPP is most closely
related to human PDZK1 (Fig. 1, C and D), a
protein identified in a yeast two-hybrid screen as a MAP17-associated protein. PDZK1 also associates with cMOAT, a multidrug resistance transporter (13). The mouse orthologue of PDZK1, named CAP70, was
purified from kidney based on its ability to associate with CFTR and
was shown to potentiate CFTR Cl
channel activity (14).
IKEPP and PDZK1 share significant identity with EBP50 and E3KARP (Fig.
1D). These proteins were first cloned as co-factors required
for cAMP-mediated inhibition of Na+/H+
exchanger 3 (30, 31) and later shown to associate with ezrin, radixin,
and moesin (15). EBP50 and E3KARP can interact with receptors, ion
channels, transporters, signaling molecules, adaptor proteins, and
proteins that regulate membrane trafficking (32-37). Interestingly,
EBP50, E3KARP, and PDZK1 associate with CFTR (14, 32, 35), a downstream
effector of GCC (33). Therefore, it will be important to test whether
IKEPP compartmentalizes GCC and CFTR together in a multiprotein complex
at the apical cell surface. It will also be important to compare the
expression, subcellular distribution, and binding partners of IKEPP and
PDZK1, since we find that CTEP can also bind PDZK1 in biochemical
assays (Fig. 4C).
Despite the overall sequence similarity between IKEPP, PDZK1, EBP50,
and E3KARP, PDZ1 and PDZ4 of IKEPP differ at critical residues
responsible for determining the specificity of the interaction between
the PDZ domain and COOH-terminal ligand. Class I PDZ domains coordinate
the interaction with a Ser/Thr residue at the
2-position of their
peptide ligands through an
B1 His residue. IKEPP PDZ4, however,
contains an
B1 Asp residue, which has been shown to preferentially
interact with a
2 Tyr, rather than a Ser/Thr (20). In IKEPP PDZ1, the
conserved His is replaced by a Tyr residue, which is predicted to
result in the preferential binding of Asp at the
2-position (23).
Interestingly, the COOH terminus of IKEPP ends in Ser-Asp-Leu-Leu,
which we predict based on sequence analysis, to be a ligand for IKEPP
PDZ1. Consequently, this interaction might regulate IKEPP PDZ1
interaction with other proteins via competitive inhibition or serve as
the basis for potential IKEPP oligomerization and the formation of a
larger signaling complex. Furthermore, the
B1 Tyr residue of IKEPP
PDZ1 is predicted to be phosphorylated (by NetPhos analysis, available
on the World Wide Web at www.cbs.dtu.dk/services/NetPhos), which
would alter the binding specificity of the PDZ domain and may serve a
regulatory mechanism for PDZ-ligand interaction. Our laboratory is
currently examining these potential regulators of IKEPP function.
Interaction of IKEPP and GCC--
Although there are few
antibodies that reliably detect endogenous GCC in sections of
intestine, functional studies, in situ hybridization, and
receptor autoradiography indicate that GCC is expressed in epithelial
cells of the gastrointestinal tract (39-41). Although a more complete
analysis of IKEPP expression and distribution is needed, our
localization studies suggest that GCC and IKEPP may be co-expressed and
co-localized at the apical cell surface in intestinal epithelial cells
(Fig. 3). Furthermore, GCC and IKEPP directly interact in biochemical
assays, and the interaction requires the COOH-terminal PDZ binding
motif of GCC (Fig. 4). When co-expressed in COS7 cells, HA-GCC and
IKEPP can be co-immunoprecipitated (Fig. 4E). Taken
together, our data support the hypothesis that GCC and IKEPP associate
in epithelial cells. However, consistent with previous reports (42), we
were unable to extract significant amounts of overexpressed (MDCK
cells) or endogenous GCC (T84 cells) from membranes to directly study
the GCC-IKEPP interaction in epithelial cells. Therefore, definitive proof that IKEPP and GCC interact in intestinal epithelial cells will
require dominant-negative approaches and functional assays.
IKEPP mRNA is also abundantly expressed in the kidney (Fig. 1,
A and B). Ligand binding assays and functional
studies suggest that GCC may be expressed in the kidney in some species
(43, 44). Therefore, IKEPP and GCC may also associate in the kidney; however, renal IKEPP complexes will probably differ from those found in
intestinal epithelial cells. Furthermore, proteins that associate with
IKEPP may be differentially expressed in distinct regions of the kidney
or gastrointestinal tract.
Functions of the GCC-IKEPP Interaction--
The trafficking,
regulation, and function of GCC are poorly understood, and there are
many potential roles for the IKEPP-GCC interaction. In well
differentiated cultured epithelial cells and in intestinal cell
lysates, GCC is found in the detergent-insoluble fraction (45). The
insolubility of GCC may be due to a direct or indirect association with
cytoskeletal elements enriched at the apical membrane. We find that
~50% of the endogenous IKEPP in cultured intestinal cells is in the
cytosolic fraction (Fig. 2C), and membrane-associated IKEPP
is easily solubilized in buffers containing 1% Triton X-100 (Fig.
4E). Therefore, IKEPP does not mediate the association of
GCC with the detergent-insoluble fraction of epithelial cells. GCC
exists as a functional dimer or trimer (46-48), and it is known that
interactions with PDZ proteins can facilitate protein oligomerization
(14, 36, 49). However, the intracellular domains of GCC are not
required for oligomer formation (48), suggesting that association with
IKEPP is not likely to play an important role in this process. Harris
et al. demonstrated that deletion of the PDZ interaction
motif at the COOH terminus of the multidrug resistance-associated
protein 2 (MRP2/cMOAT) disrupted apical targeting in transiently
transfected MDCK cells (50). However, the constructs used in this study contained a COOH terminus green fluorescent protein tag blocking the
PDZ interaction motif and interactions with PDZ proteins were not
assessed. Moyer et al. also reported that the efficient
apical trafficking of a green fluorescent protein-CFTR fusion protein required an intact CFTR COOH terminus and association with PDZ proteins
(51). In contrast, Benharouga et al. find that CFTR proteins
lacking the COOH-terminal PDZ binding motif are retained at the apical
membrane in polarized MDCK II cells (52). Thus, it is not clear whether
apical membrane proteins that bind to PDZ proteins, require the PDZ
interaction for apical trafficking or localization. We find that
GCC
4 was efficiently targeted to the apical cell surface (Fig.
5A). Thus, GCC must contain apical targeting information in
other regions of the protein, and interaction with PDZ proteins is not
required for the efficient surface expression or apical targeting of GCC.
Previous mutagenesis studies indicate that the COOH terminus of GCC is
required for catalytic function of the enzyme (4, 53). Since
association with PDZ proteins has been shown to modulate activation and
down-stream signaling of other cellular receptors (36, 54), we tested
the hypothesis that association with IKEPP regulated the catalytic
activity of GCC. We found that co-expression of IKEPP with GCC
significantly decreases STa-mediated accumulation of cGMP in
transfected cells (Fig. 5B). If the GCC-IKEPP interaction occurs within an intracellular compartment, co-expression of IKEPP could decrease the number of receptors present on the cell surface. Our
localization studies suggest that IKEPP is associated with the apical
cell surface (Fig. 3), but we also observe significant amounts of IKEPP
in the subapical compartment of Caco2 cells (Fig. 3A).
However, the Vmax of the receptor was not
significantly different when IKEPP was co-expressed (Fig.
5C), indicating that the GCC-IKEPP interaction does not
dramatically change the amount of receptor on the plasma membrane.
IKEPP-mediated inhibition of GCC is only observed in cells expressing
full-length GCC and not GCC proteins lacking the PDZ binding motif
(Fig. 5B). Thus, a physical interaction between IKEPP and
GCC is required for modulation of receptor function. Co-expression of
IKEPP and GCC would decrease STa-mediated cGMP accumulation if IKEPP
decreases the affinity of the receptor for its ligand. Alternatively,
it is possible that intra- or intermolecular interactions between CTEP
and the GCC catalytic domain maintain the enzyme in the appropriate
conformation for catalytic function. Binding of IKEPP to CTEP may
compete for these intra- or intermolecular interactions to decrease the
catalytic activity of GCC. Likewise, it is possible that co-expression
of IKEPP competes for binding of a cytosolic factor that associates
with GCC to stimulate its catalytic function. It is also possible that
IKEPP recruits an inhibitory protein to the GCC receptor complex. While
the mechanism of the inhibition of GCC catalytic activity by IKEPP is
unclear at this time, this interaction may have important implications for understanding the desensitization of GCC. Prolonged application of
STa leads to desensitization of the endogenous receptor in T84 cells
but not transfected receptors in COS7 or hEK293 cells, suggesting that
the desensitization may require the presence of an accessory protein
that is not expressed in these cells (29). Thus, it is intriguing to
speculate that a regulated interaction with IKEPP or the recruitment of
additional proteins to IKEPP-GCC multiprotein complexes is required for
GCC receptor desensitization. GCC null mice are resistant to STa but
have no obvious phenotype (55, 56), suggesting that we have much to
learn regarding the physiological role of GCC and its endogenous
ligands. We also have much to learn about mechanisms to control GCC
activation and desensitization, since the acute secretory diarrhea
caused by STa is a leading cause of pediatric death worldwide. The
identification of other proteins in IKEPP-GCC complexes may help
elucidate the role of GCC in normal physiology and may provide insights
into strategies to control excessive GCC activation by STa.
 |
ACKNOWLEDGEMENTS |
We thank Dr. David Garbers (University of
Texas Southwest Medical Center) for providing pBS.GCC and Dr. Chris Yun
(The Johns Hopkins University) for providing pBS.E3KARP. We thank Dr.
Jolanta Pucilowska for help with the immunohistochemistry and Dr.
Michael Goy for contributions to the early stages of the project. In
the Milgram laboratory, we thank Dr. Peter Mohler for advice, Mihir Patel and Cassandra Lambeth for technical assistance, and everyone else
for excellent discussions.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants R29DK50744 and HL63755 (to S. L. M.) and the University of North Carolina Center for Gastrointestinal Biology and Disease (to
S. L. M. and R. O. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence reported in this paper has been submitted
to the DDBJ/GenBankTM/EBI Data Bank with accession
number AY047359.
A Ford Foundation Fellow and Merck/UNCF Scholar. Present address:
Procter & Gamble Co., 8700 Mason Montgomery Rd., Mason, OH 45040.
§
To whom correspondence should be addressed. Dept. of Cell and
Developmental Biology, University of North Carolina at Chapel Hill, CB#
7090, Chapel Hill, NC 27599. Tel.: 919-966-9792; Fax: 919-966-1856;
E-mail: milg@med.unc.edu.
Published, JBC Papers in Press, April 11, 2002, DOI 10.1074/jbc.M202434200
 |
ABBREVIATIONS |
The abbreviations used are:
STa, heat-stable
enterotoxin;
CTEP, COOH-terminal extension peptide;
PDZ, postsynaptic density-95, disks large, zonula occludens-1;
BD, binding
domain;
HA, hemagglutinin;
MDCK, Madin-Darby canine kidney;
TRITC, tetramethylrhodamine isothiocyanate.
 |
REFERENCES |
| 1.
|
Currie, M. G.,
Fok, K. F.,
Kato, J.,
Moore, R. J.,
Hamra, F. K.,
Duffin, K. L.,
and Smith, C. E.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
947-951[Abstract/Free Full Text]
|
| 2.
|
Hamra, F. K.,
Forte, L. R.,
Eber, S. L.,
Pidhorodeckyj, N. V.,
Krause, W. J.,
Freeman, R. H.,
Chin, D. T.,
Tompkins, J. A.,
Fok, K. F.,
Smith, C. E.,
et al..
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10464-10468[Abstract/Free Full Text]
|
| 3.
|
Forte, L. R.,
Eber, S. L.,
Fan, X.,
London, R. M.,
Wang, Y.,
Rowland, L. M.,
Chin, D. T.,
Freeman, R. H.,
and Krause, W. J.
(1999)
Endocrinol.
140,
1800-1806[Abstract/Free Full Text]
|
| 4.
|
Wedel, B.,
and Garbers, D. L.
(2001)
Annu. Rev. Physiol.
63,
215-233[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Schulz, S.,
Green, C. K.,
Yuen, P. S.,
and Garbers, D. L.
(1990)
Cell.
63,
941-948[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Wada, A.,
Hasegawa, M.,
Matsumoto, K.,
Niidome, T.,
Kawano, Y.,
Hidaka, Y.,
Padilla, P. I.,
Kurazono, H.,
Shimonishi, Y.,
and Hirayama, T.
(1996)
FEBS Lett.
384,
75-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Deshmane, S. P.,
Parkinson, S. J.,
Crupper, S. S.,
Robertson, D. C.,
Schulz, S.,
and Waldman, S. A.
(1997)
Biochemistry
36,
12921-12929[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Chevray, P. M.,
and Nathans, D.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5789-5793[Abstract/Free Full Text]
|
| 9.
|
Smith, F. D.,
Oxford, G. S.,
and Milgram, S. L.
(1999)
J. Bio. l Chem.
274,
19894-19900
|
| 10.
|
Trotter, K. W.,
Fraser, I. D.,
Scott, G. K.,
Stutts, M. J.,
Scott, J. D.,
and Milgram, S. L.
(1999)
J. Cell Biol.
147,
1481-1492[Abstract/Free Full Text]
|
| 11.
|
Mohler, P. J.,
Kreda, S. M.,
Boucher, R. C.,
Sudol, M.,
Stutts, M. J.,
and Milgram, S. L.
(1999)
J. Cell Biol.
147,
879-890[Abstract/Free Full Text]
|
| 12.
|
Pucilowska, J. B.,
McNaughton, K. K.,
Mohapatra, N. K.,
Hoyt, E. C.,
Zimmermann, E. M.,
Sartor, R. B.,
and Lund, P. K.
(2000)
Am. J. Physioll.
279,
G1307-1322
|
| 13.
|
Kocher, O.,
Comella, N.,
Gilchrist, A.,
Pal, R.,
Tognazzi, K.,
Brown, L. F.,
and Knoll, J. H.
(1999)
Lab. Invest.
79,
1161-1170[Medline]
[Order article via Infotrieve]
|
| 14.
|
Wang, S.,
Yue, H.,
Derin, R. B.,
Guggino, W. B.,
and Li, M.
(2000)
Cell
103,
169-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Reczek, D.,
Berryman, M.,
and Bretscher, A.
(1997)
J. Cell Biol.
139,
169-179[Abstract/Free Full Text]
|
| 16.
|
Gisler, S. M.,
Staglijar, I.,
Traebert, M.,
Bacic, D.,
Biber, J.,
and Murer, H.
(2001)
J. Biol. Chem.
276,
9206-9213[Abstract/Free Full Text]
|
| 17.
|
Doyle, D. A.,
Lee, A.,
Lewis, J.,
Kim, E.,
Sheng, M.,
and MacKinnon, R.
(1996)
Cell
85,
1067-1076[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Sheng, M.,
and Sala, C.
(2001)
Annu. Rev. Neurosci.
24,
1-29[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Harris, B. Z.,
and Lim, W. A.
(2001)
J. Cell Sci.
114,
3219-3231[Medline]
[Order article via Infotrieve]
|
| 20.
|
Songyang, Z.,
Fanning, A. S., Fu, C., Xu, J.,
Marfatia, S. M.,
Chishti, A. H.,
Crompton, A.,
Chan, A. C.,
Anderson, J. M.,
and Cantley, L. C.
(1997)
Science
275,
73-77[Abstract/Free Full Text]
|
| 21.
|
Karthikeyan, S.,
Teil, L.,
and Ladias, J. A.
(2001)
J. Biol. Chem.
276,
19683-19686[Abstract/Free Full Text]
|
| 22.
|
Daniels, D. L.,
Cohen, A. R.,
Anderson, J. M.,
and Brünger, A. T.
(1998)
Nat. Struct. Biol.
5,
317-325[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Stricker, N. L.,
Christopherson, K. S., Yi, B. A.,
Schatz, P. J.,
Raab, R. W.,
Dawes, G.,
Bassett, D. E., Jr.,
Bredt, D. S.,
and Li, M.
(1997)
Nat. Biotechnol.
15,
336-342[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Nandi, A.,
Bhandari, R.,
and Visweswariah, S. S.
(1997)
J. Cell. Biochem.
66,
500-511[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Waldman, S. A.,
Kuno, T.,
Kamisaki, Y.,
Chang, L. Y.,
Gariepy, J.,
O'Hanley, P.,
Schoolnik, G.,
and Murad, F.
(1986)
Infect. Immun.
51,
320-326[Abstract/Free Full Text]
|
| 26.
|
Kim, S. K.
(1997)
Curr. Opin. Cell Biol.
9,
853-859[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Brown, D.,
and Stow, J. L.
(1996)
Physiol. Rev.
76,
245-297[Abstract/Free Full Text]
|
| 28.
|
Straight, S. W.,
Chen, L.,
Karnak, D.,
and Margolis, B.
(2001)
Mol. Biol. Cell.
12,
1329-1340[Abstract/Free Full Text]
|
| 29.
|
Bakre, M. M.,
Ghanekar, Y.,
and Visweswariah, S. S.
(2000)
Eur. J. Biochem.
267,
179-187[Medline]
[Order article via Infotrieve]
|
| 30.
|
Weinman, E. J.,
Steplock, D.,
Wang, Y.,
and Shenolikar, S.
(1995)
J. Clin. Invest.
95,
2143-2149[Medline]
[Order article via Infotrieve]
|
| 31.
|
Yun, C. H., Oh, S.,
Zizak, M.,
Steplock, D.,
Tsao, S.,
Tse, C. M.,
Weinman, E. J.,
and Donowitz, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3010-3015[Abstract/Free Full Text]
|
| 32.
|
Short, D. B.,
Trotter, K. W.,
Reczek, D.,
Kreda, S. M.,
Bretscher, A.,
Boucher, R. C.,
Stutts, M. J.,
and Milgram, S. L.
(1998)
J. Biol. Chem.
273,
19797-19801[Abstract/Free Full Text]
|
| 33.
|
Cao, T. T.,
Deacon, H. W.,
Reczek, D.,
Bretscher, A.,
and von Zastrow, M.
(1999)
Nature
401,
286-290[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Hall, R. A.,
Spurney, R. F.,
Premont, R. T.,
Rahman, N.,
Blitzer, J. T.,
Pitcher, J. A.,
and Lefkowitz, R. J.
(1999)
J. Biol. Chem.
274,
24328-24334[Abstract/Free Full Text]
|
| 35.
|
Sun, F.,
Hug, M. J.,
Lewarchik, C. M.,
Yun, C. H.,
Bradbury, N. A.,
and Frizzell, R. A.
(2000)
J. Biol. Chem.
275,
29539-29546[Abstract/Free Full Text]
|
| 36.
|
Maudsley, S.,
Zamah, A. M.,
Rahman, N.,
Blitzer, J. T.,
Luttrell, L. M.,
Lefkowitz, R. J.,
and Hall, R. A.
(2000)
Mol. Cell. Biol.
20,
8352-8363[Abstract/Free Full Text]
|
| 37.
|
Reczek, D.,
and Bretscher, A.
(2001)
J. Cell Biol.
153,
191-206[Abstract/Free Full Text]
|
| 38.
|
Chao, A. C., De,
Sauvage, F. J.,
Dong, Y. J.,
Wagner, J. A.,
Goeddel, D. V.,
and Gardner, P.
(1994)
EMBO Journal
13,
1065-1072[Medline]
[Order article via Infotrieve]
|
| 39.
|
Li, Z.,
and Goy, M. F.
(1993)
Am. J. Physiol.
265,
G394-G402[Medline]
[Order article via Infotrieve]
|
| 40.
|
Swenson, E. S.,
Mann, E. A.,
Jump, M. L.,
Witte, D. P.,
and Giannella, R. A.
(1996)
Biochem. Biophys. Res. Comm.
225,
1009-1014[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Cohen, M. B.,
Mann, E. A.,
Lau, C.,
Henning, S. J.,
and Giannella, R. A.
(1992)
Biochem. Biophys. Res. Comm.
186,
483-490[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Hakki, S.,
Crane, M.,
Hugues, M.,
O'Hanley, P.,
and Waldman, S. A.
(1993)
Int. J. Biochem.
25,
557-566[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Carrithers, S. L.,
Taylor, B.,
Cai, W. Y.,
Johnson, B. R.,
Ott, C. E.,
Greenberg, R. N.,
and Jackson, B. A.
(2000)
Regul. Pept.
95,
65-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Forte, L. R.,
London, R. M.,
Freeman, R. H.,
and Krause, W. J.
(2000)
J. Physiol.
278,
F180-191
|
| 45.
|
Hakki, S.,
Robertson, D. C.,
and Waldman, S. A.
(1993)
Biochim. Biophys. Acta
1152,
1-8[Medline]
[Order article via Infotrieve]
|
| 46.
|
Vaandrager, A. B.,
Van Der Wiel, E.,
Hom, M. L.,
Luthjens, L. H.,
and De Jonge, H. R.
(1994)
J. Biol. Chem.
269,
16409-16415[Abstract/Free Full Text]
|
| 47.
|
Vijayachandra, K.,
Guruprasad, M.,
Bhandari, R.,
Manjunath, U. H.,
Somesh, B. P.,
Srinivasan, N.,
Suguna, K.,
and Visweswariah, S. S.
(2000)
Biochemistry
39,
16075-16083[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Hirayama, T.,
Wada, A.,
Hidaka, Y.,
Fujisawa, J.,
Takeda, Y.,
and Shimonishi, Y.
(1993)
Microb. Pathog.
15,
283-291[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Raghuram, V.,
Mak, D. D.,
and Foskett, J. K.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1300-1305[Abstract/Free Full Text]
|
| 50.
|
Harris, M. J.,
Kuwano, M.,
Webb, M.,
and Board, P. G.
(2001)
J. Biol. Chem.
276,
20876-20881[Abstract/Free Full Text]
|
| 51.
|
Moyer, B. D.,
Denton, J.,
Karlson, K. H.,
Reynolds, D.,
Wang, S.,
Mickle, J. E.,
Milewski, M.,
Cutting, G. R.,
Guggino, W. B., Li, M.,
and Stanton, B. A.
(1999)
J. Clin. Invest.
104,
1353-1361[Medline]
[Order article via Infotrieve]
|
| 52.
| Benharouga M., Sharma, M., Lechardeur, D., Drzymala, L., Zerangue, N.,
Lukacs, G. L. Fifteenth Annual North American Cystic Fibrosis
Conference, 2001, abstract 10
|
| 53.
|
Deshmane, S. P.,
Carrithers, S. L.,
Parkinson, S. J.,
Crupper, S. S.,
Robertson, D. C.,
and Waldman, S. A.
(1995)
Biochemistry
34,
9095-9102[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Hall, R. A.,
Premont, R. T.,
Chow, C. W.,
Blitzer, J. T.,
Pitcher, J. A.,
Claing, A.,
Stoffel, R. H.,
Barak, L. S.,
Shenolikar, S.,
Weinman, E. J.,
Grinstein, S.,
and Lefkowitz, R. J.
(1998)
Nature
392,
626-630[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Mann, E. A.,
Jump, M. L., Wu, J.,
Yee, E.,
and Giannella, R. A.
(1997)
Biochem. Biophys. Res. Commun.
239,
463-466[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Schulz, S.,
Lopez, M. J.,
Kuhn, M.,
and Garbers, D. L.
(1997)
J. Clin. Invest.
100,
1590-1595[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. S. Benn, D. Ajibade, A. Porta, P. Dhawan, M. Hediger, J.-B. Peng, Y. Jiang, G. T. Oh, E.-B. Jeung, L. Lieben, et al.
Active Intestinal Calcium Transport in the Absence of Transient Receptor Potential Vanilloid Type 6 and Calbindin-D9k
Endocrinology,
June 1, 2008;
149(6):
3196 - 3205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Donowitz and X. Li
Regulatory Binding Partners and Complexes of NHE3
Physiol Rev,
July 1, 2007;
87(3):
825 - 872.
[Abstract]
[Full Text]
[PDF]
|
 |
|